We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Greenovation´s BryoTechnology Substantially Improves Yields of Pharmaceutical Proteins
News

Greenovation´s BryoTechnology Substantially Improves Yields of Pharmaceutical Proteins

Greenovation´s BryoTechnology Substantially Improves Yields of Pharmaceutical Proteins
News

Greenovation´s BryoTechnology Substantially Improves Yields of Pharmaceutical Proteins

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Greenovation´s BryoTechnology Substantially Improves Yields of Pharmaceutical Proteins"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

GREENOVATION has substantially enhanced the yields of pharmaceutical proteins produced using its moss-based BryoTechnology. Targeted genetic modifications, improved fermentation procedures and optimized production processes mean that the new and highly productive BryoMaster® cell lines can secrete higher yields of complex molecules directly into the culture medium.

This includes producing antibodies in their active form, with enhanced antibody-dependent cell mediated cytoxity (ADCC). Adding in the company's BryoSpeed® technology means that Greenovation can produce sufficient protein for quality assessment within only seven days.

“Our intensive research efforts are now bearing fruit” says Dr. Thomas Frischmuth, CEO of Greenovation. “The recent yield improvements once again underline the viability of moss-based cGMP-production as a beneficial alternative to mammalian cells in steel-tanks.”

The moss-made proteins manufactured using Greenovation's BryoTechnology have very high levels of glycan consistency and batch-to-batch stability. Combining the reliability of the production process and the ease of the modular single use-based approach means that BryoTechnology is prepared to face production challenges of the facility of the future.

Advertisement